Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia

Follow Drugslib on

Newton, MA, February 24, 2025 – Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient out comes in oncology and inflammatory disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AUTX-703 for the treatment of patients with relapsed or refractory (r/r) acute myelogenous leukemia (AML).

AUTX-703 is a novel, first-in-class, oral KAT2A/B degrader discovered and developed by Auron using its AURIGIN™ Platform. The Company has previously presented preclinical data supporting the ability of AUTX-703 to provide a significant survival advantage in AML. Following the FDA’s recent clearance of its Investigational New Drug (IND) application, Auron plans to initiate clinical development of AUTX-703 in hematological malignancies in the first quarter of 2025.

“We are gratified by the FDA’s recognition of AUTX-703’s potential as an important, novel treatment option for relapsed or refractory AML patients, a community that remains in desperate need of new therapies,” said Kate Yen, Ph.D., Founder and Chief Executive Officer of Auron. “The FDA Fast Track Designation underscores the urgent need for innovative treatments for these patients and this milestone comes at a pivotal moment as we prepare to advance AUTX-703 into the clinic. Our team is energized by the potential to bring a first-in-class therapy to patients who have limited effective options today, while simultaneously exploring the broader applications of KAT2A/B modulation.”

The FDA’s FastTrack program is designed to facilitate the development and expedite the review of medicines with the potential to treat serious or life-threatening conditions and address unmet medical needs. Specifically, Fast Track designation facilitates more frequent interactions with the FDA over the course of a drug’s development and enables Accelerated Approval and Priority Review eligibility, if relevant criteria are met.

AML is an aggressive blood cancer characterized by the rapid growth of abnormal cells that build up in the bone marrow and interfere with normal blood cell production. Patients with relapsed or refractory AML face particularly poor outcomes, with five-year survival rates of approximately 10%1, highlighting the critical need for novel therapeutic approaches.

About Auron Therapeutics

Auron Therapeutics is a platform-powered, product-driven company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease. Auron pioneered its AURIGIN™ platform, which uses AI and machine learning to compare cell states and identify novel drug targets, optimal development models, and biomarkers to facilitate proper patient selection, ultimately accelerating the development of effective and durable therapies. Using AURIGIN, the Company is building a pipeline of small molecule targeted therapies, led by a first-in-class, oral KAT2A/B degrader, AUTX-703, which is being developed for the treatment of both hematologic malignancies and solid tumors. For more information, please visit aurontx.com and follow us on LinkedIn.

Source: Auron Therapeutics

Posted : 2025-02-26 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords